Liu Qian, Vice President of AstraZeneca China said on Friday that in Q2 2023, the retail market of chronic disease drugs for hypertension, hyperlipemia, and hyperglycemia, has declined significantly.
Editor:
Alexander
Vice President of AstraZeneca China said the retail market of chronic disease drugs for hypertension, hyperlipemia, and hyperglycemia, has declined significantly
Most Popular
- 1 Meituan's LongCat team officially releases and open-sources LongCat-Video
- 2 iPhone Air now available in China, and resale prices instantly spiking
- 3 Airbus launches new assembly line in China
- 4 Dialogue with Scientists | An Innovator's Journey: From DNA Sequencing to AI-Driven Natural Health
- 5 DiDi's 99Food Expands to Rio de Janeiro, Intensifying Brazil's Food Delivery Battle
- 6 Tencent Launches Oracle Bone Script AI Agent
- 7 China's A-Share Market Breaches 4,000 Points: A Historic Milestone Signifying a ‘Slow Bull’ Tech-Driven New Normal
川公网安备 51019002001991号
